- Record: found
- Abstract: not found
- Article: not found
Comparative Effectiveness and Safety of Long-Acting β2-Agonist-Long-Acting Muscarinic Antagonists vs Long-Acting β2-Agonist-Inhaled Corticosteroid Treatment of COPD in Real-World Clinical Practice
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are
recommended as initial maintenance treatments for COPD, with their combination (LABA-LAMA)
advocated as the disease progresses. Randomized trials comparing the effectiveness
of this combination with the alternative combination of LABA with inhaled corticosteroid
(LABA-ICS) have reported conflicting data, while there are no real-world comparative
effectiveness and safety studies of these regimens in clinical practice settings.